Rp-8-CPT-cAMP is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs, 8-CPT-cyclic AMP and Rp-cyclic AMPS .[1] It functions as a site-selective inhibitor of protein kinase A (PKA) type I and II, with preference towards site A of type I and site B of type II.2 By occupying cAMP binding sites at the regulatory subunit of PKA, Rp-8-CPT-cAMP prevents the kinase holoenzyme from dissociative activation.[2],[3]
Reference:
[1]. Schwede, F., Maronde, F., Genieser, H., et al. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacology & Therapeutics 87(2), 199-226 (2000).
[2]. Dostmann, W.R., Taylor, S.S., Genieser, H.G., et al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates. J. Biol. Chem. 265(18), 10484-10491 (1990).
[3]. Gjertsen, B.T., Mellgran, G., Otten, A., et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1β action. J. Biol. Chem. 270(35), 20599-20607 (1995).